A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Stosowanie leku Lu-177-PSMA-617 od 1 stycznia 2021 roku lub później
- •Wcześniejsze leczenie co najmniej jednym inhibitorem receptor androgenowego
- •Leczenie taksanem przed lub po leku Lu-177-PSMA-617
- •Zdiagnozowany rak prostaty oporny na kastrację przed datą rozpoczęcia obserwacji
- •Wiek co najmniej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 115 Years
- Last updated (source)
- July 16, 2026
- Sex
- Male only
Locations (1)
Novartis
East Hanover, United States
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.